fnarena4h
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
YORVIPATH is a first-in-class PTH replacement therapy. A prodrug of parathyroid hormone (PTH [1-34]), YORVIPATH is administered subcutaneously once daily, with sustained release of active PTH designed ...
fnarena4h
Silicon Quantum Computing achieves world-leading accuracy of Grover’s algorithm without error correction
Silicon Quantum Computing (SQC), a pioneer in quantum computing and atomic manufacturing, today announced that it has ...
fnarena4h
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
MELBOURNE, Australia and INDIANAPOLIS, Ind., Feb. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: ...
fnarena17h
Rudi’s View: Best Ideas & Conviction Calls
Crestone's Best Sector Ideas are an attempt to identify the best in breed business models for major industry group sectors for long-term oriented investors. Anticipated performance over the next three ...
fnarena23h
Temple & Webster Embraces The Future
An exceptional earnings beat from Temple & Webster was driven by a simultaneous increase in both revenue and margins, with a ...